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declined from 76% to 31% as a share of all uses from 1994 to 2007, while substantial 
increases in use occurred for bipolar affective disorder (5% to 39%) and depression 
(8% to 15%). The fraction of atypical antipsychotic use for indications with insufﬁ -
cient evidence of efﬁ cacy increased from 32% in 1994 to 58% in 2007, representing
26 million prescriptions and $7.3 billion dollars in expenditures in 2007. During 2007, 
primary care physicians accounted for 21% of visits where an antipsychotic was
used, as compared with psychiatrists (77%) or physicians from other specialties 
(2%). Antipsychotic use in settings of insufﬁ cient evidence was similar among primary
care physicians and psychiatrists. CONCLUSIONS: The scope and costs of this 
expansion, due to both clinical innovation and overuse, demonstrate the importance
of efforts to limit the clinical application of antipsychotics to settings of sufﬁ cient 
evidence.
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ADULT ADHD IN THE UNITED STATES: A COMPARISON OF 2 METHODS
TO ESTIMATE PREVALENCE
Montejano LB1, Sasane R2, Hodgkins P2, Huse D3
1Thomson Reuters, Washington, DC, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 
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OBJECTIVES: To validate adult ADHD prevalence estimates in a US health care
claims database. METHODS: A commercial research database (MarketScan from 
Thomson Reuters; employer clients only) was used to estimate the annual prevalence 
of adult ADHD from 2002 to 2007. Patients (18–64 years) diagnosed with ADHD 
(ICD-9) on at least 2 occasions within 12 months were counted in each year they 
had a diagnostic/drug claim indicating ADHD. These prevalence rates were compared
with rates from a US epidemiological study which estimated adult ADHD prevalence 
using clinical interviews of respondents (18–44 years) from the 2005 National Comor-
bidity Survey replication (NCS-R; Kessler et al, 2006). RESULTS: In MarketScan
the prevalence of diagnosed and treated ADHD in US adults was 1.24 per 1000 
members in 2002, increasing annually to more than triple in 2007 (4.02 per 1000). 
The proportion of females: males with ADHD increased yearly. Prevalence per 1000
grew faster among 18–24 than 25–64 year olds. ADHD with hyperactivity was more
prevalent than ADHD without hyperactivity. In contrast, the NCS-R study reported
a higher ADHD prevalence (44 per 1000) in 2005 in the 18–44 group, with more 
males than females diagnosed with ADHD. Prevalence estimates from our study 
increased when correcting for differences between studies in age range (18–64 versus 
18–44 years; 4.59 per 1000) and number of diagnoses (2 vs 1; 5.03 per 1000). In the
NCS-R study, only 10.9% of individuals who were diagnosed received treatment.
Thus, the number of treated patients in the NCR-S study (4.796 per 1000) is close to 
the 4.02 per 1000 reported from the claims database. CONCLUSIONS: The estimated 
prevalence of adult ADHD in diagnosed and treated patients based on claims data is 
similar to that based on clinical interviews, validating the use of claims data to estimate 
prevalence.
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OBJECTIVES: To evaluate the risk of injury associated with attention-deﬁ cit hyper-
activity disorder (ADHD) using information from an employee database. METHODS:
Using the MarketScan Commercial Claims and Encounters Database from Thomson 
Reuters, patients aged 18 to 64 years and diagnosed with ADHD (N  31,752) were 
matched by similarity in demographics and data availability 3:1 to controls without 
ADHD (N  95,256) or 1:1 to controls diagnosed with depression (N  29,965). 
Patients with ADHD were also stratiﬁ ed into compliant (Medication Possession Ratio 
[MPR] q0.8; N  8654), partially compliant (0.3 a MPR  0.8; N  5233) and non-
compliant (MPR  0.3; N  4007) cohorts. Risk of injury was compared between
groups for January to December 2006. Multivariate analyses controlled for treatment
differences between groups that remained after matching. RESULTS: Injury rates were 
higher in the ADHD group than in the non-ADHD control group (21.6% vs 15.7%,
p  0.001) and depression group (21.4% vs. 20.5%, p  0.0085), and higher in the 
compliant group than in the partially compliant (22.8% vs 20.3, p  0.0004) and 
noncompliant (22.8% vs 17.8%, p  0.001) groups. In multivariate analyses, risk of 
injury was higher in the ADHD group than in the non-ADHD (1.3194 odds ratio 
[OR], p  0.01) and depression control groups (1.1263 OR, p  0.01) and higher in
compliant and partially compliant patients than in noncompliant patients (1.2633 and
1.664 OR, respectively, p  0.01). Comorbid depression, anxiety and substance abuse 
predicted a higher risk of injury in the ADHD versus control groups (p  0.01) and 
in compliant/partially compliant patients versus noncompliant patients (p  0.01), with 
magnitude equal to or exceeding that of the ADHD group alone. CONCLUSIONS:
Patients with ADHD had higher risk of injury than similarly matched patients without 
ADHD or with depression, suggesting important implications for workplace safety
and liability.
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RISK ASSESSMENT OF POISONING WITH DRUGS OF THERAPEUTIC 
IMPORTANCE BY TOXICOVIGILANCE
Sam KG, Tunga G, Pandey S
Manipal University, Manipal, Karnataka, India
OBJECTIVES: Toxicovigilance studies were carried out with the aim to determine the
health hazards, treatment and outcome of therapeutic drug overdose. METHODS: All 
therapeutic drug poisoned patients admitted to a tertiary care South Indian hospital. 
were evaluated for predisposing factors manner of exposure, severity at admission,
treatment, hospitalization period, clinical status at discharge, , in order to implement 
medication safety programs. RESULTS: A total of 200 patients were admitted with 
therapeutic drug overdose. A total of 153 cases intentionally ingested the drugs, while 
29 cases had overdose during routine therapy, and 18 cases had ingested the drugs 
accidentally. Depression was the major predisposing factor for intentional self harm. 
Most of the poisoning with therapeutic drugs occurred due to intentional self harm n 
 153 (76.5%). Other manner of exposures include overdose during therapeutic use
n  29 (14.5%) or accidental exposure n  18 (9%). There was a signiﬁ cant (P 
0.001) association of employment and occupational status on the manner of exposure. 
The mean GCS, APACHE II scores, PMR and PSS for all the patients was 8.46 o 3.6; 
20.63 o 5.0; 38.58 o 16.1 and 2.96 o 0.79 (Mean o SD) respectively. The mean GCS 
score was signiﬁ cantly (P  0.033) different between various class of poisoning. The
APACHE II scores were not signiﬁ cantly (P  0.05) different between various drug 
classes. The mean severity scores was signiﬁ cantly (P  0.016) different between 
various class of drugs. The treatment provided was empirical and symptomatic with 
differing decontamination procedures. The average hospitalization period was 6.68 o
4.9 days with a median of 6 days range (3–8). Majority of them 189(94.5%) improved,
while 5 patients were discharged with severe sequele, and six patients expired during 
hospital stay. CONCLUSIONS: The extent of harm caused due to therapeutic drug 
poisoning can be minimized by systematically estimating the severity at triage and
providing treatment as per standardized guidelines.
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A META-ANALYSIS OF EFFICACY AND SAFETY OF PREGABALIN AND
CLONAZEPAM IN THE TREATMENT OF ANXIETY DISORDERS
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OBJECTIVES: The purpose of this study was to evaluate the relative efﬁ cacy and
safety of pregabalin and clonazepam in the treatment of anxiety disorders. METHODS:
A meta-analysis was performed with randomized clinical trials (RCTs) where pregaba-
lin or clonazepam were used for any anxiety disorders. Effectiveness was assessed with
the Hamilton Anxiety Rating Scale (HAM-A); safety with the frequency and type of 
adverse events (AEs). RCT were searched in July 2008 in Medline, EMBASE, PsycInfo, 
CINAHL and the Cochrane Collaboration. Two independent reviewers identiﬁ ed the 
abstracts, full articles, and then extracted data; results were compared and settled 
through consensus. RCT included both drugs and its comparison with placebo. Odds 
ratios and weighted means differences (WMD) were calculated. Both, ﬁ xed and 
random effects models were employed in the analysis. RESULTS: From 1893 abstracts, 
we obtained 40 RCT, 23 were excluded (unacceptable designs, insufﬁ cient outcome 
data, no placebo control) leaving 17. Seven pregabalin studies were used to evaluate 
its effectiveness and safety; four clonazepam studies for effectiveness and six for safety.
Clonazepam studies included panic disorder and social phobia. Six of seven pregabalin
studies were in generalized anxiety disorder and one for social anxiety disorder. We 
found that both drugs signiﬁ cantly diminished anxiety levels after four to 32 weeks 
of treatment. Among clonazepam studies the frequency of AEs was higher than
placebo by nearly 50%; with pregabalin, less than 30%. We didn’t found any head-
to-head studies with pregabalin and clonazepam and no statistical difference in anxiety 
level reduction was distinguished between drugs, WMD in HAM-A: 1.2(CI95% 1.13, 
3.54). However, clonazepam showed higher AE rates than pregabalin in somnolence 
(OR 0.54; 95%CI 0.44–0.66), headache (OR 0.50; 0.34–0.74), blurred vision (OR 
0.36; 0.13–0.98) and cognitive impairment (OR 0.25; 0.09–0.72). CONCLUSIONS:
Clonazepam and pregabalin are effective in diminishing anxiety levels in several
anxiety disorders, although clonazepam seems to cause a higher frequency of AEs.
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BUDGETARY IMPACT OF WELL DIRECTED USE OF PALIPERIDONE ER IN
GERMANY
Sindern J1, Mehnert A2, Schroeder-Bernhardi D3
1Janssen-Cilag GmbH, Neuss, Germany, 2Janssen-Cilag GmbH, Neuss, NRW, Germany, 3IMS 
Health GmbH & Co. OHG, Frankfurt/Main, Hessen, Germany
OBJECTIVES: Purpose of this analysis was to quantify the subgroup of schizophrenia
patients with potential treatment beneﬁ ts associated with the oral atypical antipsy-
chotic Paliperidone ER (PER) according to its clinical proﬁ le (limited liability for 
hepatic drug-drug interactions (DDI) via CYP450) and to assess the budgetary impact
of targeted use of PER for treatment of these patients. METHODS: In a retrospective 
study of longitudinal patient data from Germany using IMS Disease Analyzer, medical
records from patients with at least one diagnosis of schizophrenia (ICD10 F20-F29) 
between July 2007 and June 2008 were analyzed. For the last quarter of the study 
period prescriptions of antipsychotic and concomitant medication of schizophrenia 
Abstracts A175
patients were analyzed to identify subgroups of patients regarding potential for DDI 
and antipsychotic treatment costs. RESULTS: Of 8221 schizophrenia patients identi-
ﬁ ed in the data base 28.2% had co-prescriptions with potential for DDI and were 
regarded as subgroup for well directed use of PER. The average antipsychotic costs/
quarter of these patients were €399.0/patient for atypicals; €276.5/patient for generic
and €613.2/patient for patent protected atypicals (incl. PER). The average treatment 
costs/quarter for PER were 551.0 EUR/patient. PER treatment of all patients treated 
with patent protected atypicals at risk for DDI would reduce the overall antipsychotic
expenditure for schizophrenia by 1.9%. PER treatment of all atypical patients 
with potential DDI would increase the schizophrenia antipsychotics budget by 
8.0%. CONCLUSIONS: The budgetary impact of well directed used PER is limited
by the share of schizophrenia patients with potential DDI. As PER is associated with 
10% lower treatment costs compared to patent protected atypicals, PER could reduce
costs if used instead of other patent protected atypicals. Reduced risk for DDI com-
plications with PER may lead to additional cost savings that are not captured in this 
analysis.
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OBJECTIVES: To investigate the costs of dementia in Hungary, analyzing the distribu-
tion of direct and indirect costs, considering also the costs of caregivers. On basis of 
prevalence estimations from previous dementia studies we extrapolated the mean cost
issues and estimated the burden of dementia for the population aged 50 in Hungary. 
METHODS: A cross-sectional study of 88 consecutive patients with dementia and
their caregivers was conducted in 2008 involving physicians and nurses of 3 GP and
1 outpatient practices. Resource Utilization in Dementia (RUD), Mini Mental State
Examination (MMSE), and the health related quality of life EuroQoL (EQ-5D) ques-
tionnaires were applied. Using 2007 prices we established the proportion of the main
cost-drivers and categorized cost-data by patients’ age and MMSE scores. RESULTS:
Patients (59% female) were involved with clinical characteristics of mean MMSE 16.7
(SD 7.24), EQ-5D 0.401 (SD 0.327.), 59% were female, mean age was 78 years (SD 
8.5). The average monthly direct costs per patient were 282 (SD 532) euros, mean
indirect costs were 53 (SD 187) euros/patient/month. Total costs by age-groups (total
sample, 65–74, 75–84 and 85 or more years) considering mental status (MMSE score 
level of 0–18, 19–24 and 25–30) within each were 176, 234, 108, 131 and 375, 588,
166, 67 and 418, 569, 262, 121 euros/patient/month, respectively. Dementia-related 
health services and indirect costs (income loss of caregivers) had the highest shares of 
the whole, 32%–32%for both. CONCLUSIONS: Costs of increase by age and severity
of the disease (measured by MMSE scores). At national level, in 2008 the estimated
direct costs of dementia were 255 million euros with 48 million euros indirect costs. 
Trends show a remarkable growth in the number of the demented patients. Therefore,
an increase of disease burden of dementia is expected in the future.
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COST-BENEFIT ANALYSIS OF FOUR ANTIPSYCHOTIC DRUGS FOR THE
TREATMENT OF SCHIZOPHRENIA IN COLOMBIA
Rosselli D1, DeAntonio R2, Córdoba R1
1Independiente, Bogotá, DC, Colombia, 2Independent, Bogota, Colombia
OBJECTIVES: To compare, through cost-beneﬁ t analysis, a long-acting atypical anti-
psychotic (risperidone) with two second-generation oral antipsychotics (olanzapine
and clozapine) and a “typical” prolonged action antipsychotic (pipotiazine).
METHODS: We designed a decision tree that included only direct costs, from the 
third party payer perspective and a single year time frame. Main epidemiological
variables, obtained mostly from international literature and clinical trials, were adher-
ence, relapses with and without hospitalization, and side effects. Local costs were 
obtained from Colombian health insurers and providers. RESULTS: According to the
model, the use of long acting risperidone injection was associated with the lowest 
overall costs to the system (US$5169 per year) followed closely by clozapine (US$5221) 
whose long term metabolic effects were not included in the model. Either one of these
drugs would save around US$ 800 per year when compared with olanzapine
(US$6087), and more than US$1000 when compared with pipotiazine (US$6544), the 
least expensive of the group and currently the standard of care in most patient groups.
CONCLUSIONS: Despite their apparent higher costs, atypical antipsychotics can be 
cost saving through their reduction in relapses and hospitalizations. The economic
beneﬁ t, particularly with risperidone injection which had the lowest side effects, would
be added to the direct and indirect beneﬁ ts to the patients and their communities due 
mainly to relapse reduction.
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HEALTH CARE COSTS ASSOCIATED WITH TREATMENT OF BIPOLAR
DISORDER USING A MOOD STABILIZER PLUS ADJUNCTIVE
ARIPIPRAZOLE, QUETIAPINE, RISPERIDONE, OLANZAPINE OR
ZIPRASIDONE
Jing Y1, Kim E1, Pikalov A2, Tran QV2
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OBJECTIVES: Bipolar disorder has an associated economic burden due to its treat-
ment, including medication and hospitalization costs as well as costs associated with
treatment of comorbid medical conditions. This study compared health care costs in 
patients treated with a mood stabilizer and adjunctive aripiprazole versus adjunctive 
olanzapine, quetiapine, risperidone or ziprasidone. METHODS: A retrospective 
propensity score-matched cohort study was conducted in the LabRx integrated
claims database from January 2003 through December 2006. Patients aged 18–65 
years with bipolar disorder and 180 days of pre-index enrolment without atypical
antipsychotic therapy and 90 days post-index enrolment were eligible for inclusion.
Mood stabilizer therapy was initiated prior to index atypical prescription. Generalized
gamma regressions were used to compare the total health care costs of patients 
treated with adjunctive aripiprazole and patients treated with adjunctive olanzapine, 
quetiapine, risperidone or ziprasidone. RESULTS: After controlling for differences in 
baseline characteristics and pre-index cost, psychiatric costs and subtotal psychiatric 
and general medical cost were signiﬁ cantly higher for all adjunctive atypical antipsy-
chotics than adjunctive aripiprazole (p  0.001). There was no signiﬁ cant difference
in general medical costs between aripiprazole and ziprasidone, olanzapine, or quetiap-
ine. Aripiprazole medication costs were signiﬁ cantly higher than for quetiapine and 
risperidone (p  0.001) but not olanzapine or ziprasidone. Total health care costs
were signiﬁ cantly higher for ziprasidone, olanzapine, or risperidone (p  0.001) than 
aripiprazole but not for quetiapine. CONCLUSIONS: Adjunctive aripiprazole may 
have economic beneﬁ ts over other atypical antipsychotics in terms of lower psychiatric 
treatment costs of care than adjunctive olanzapine, quetiapine, risperidone or ziprasi-
done, and lower total health care costs than adjunctive olanzapine, risperidone or
ziprasidone.
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HEALTH CARE RESOURCE UTILIZATION ANALYSIS OF PRE/POST
LONG-ACTING RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA 
AND SCHIZOAFFECTIVE DISORDERS IN THREE REGIONAL PUBLIC 
HOSPITALS IN HONG KONG
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1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The Chinese University of Hong
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OBJECTIVES: The objective of this study was to compare the health care utilization 
and associated cost in a group of schizophrenia and schizoaffective patients pre and 
post risperidone long-acting injection (RLA) treatment. METHODS: This was a ret-
rospective cost analysis study. Data was gathered solely from hospital records, which 
were reviewed for data pertaining to utilization of health care resources. The study
was performed from a public health care institute’s perspective. Patients studied were
from three public hospitals in Hong Kong. They were started on antipsychotic treat-
ment but later on switched to RLA therapy due to adverse effects, poor response or 
whatever reasons and remained on risperidone for a minimum of 12 months. The 
initial RLA administration date served as the index date. Study periods included 12-
month pre and 24-month post the index date and patients served as their own control.
Cost data collected included medications, laboratory procedures, other more sophis-
ticated investigational procedures (e.g. CT, MRI), regular and extra outpatient clinic 
visits, emergency room utilization, hospitalization, and other health services such as 
special counseling sessions. RESULTS: A total of 180 patients who received RLA
treatment were identiﬁ ed from 2 public general and 1 psychiatric hospitals in Hong 
Kong over the period of 2003–2006. The overall annual cost of treatment before and
after RLA injection was HKD80.5 million (USD10.3 million; 1USD  7.8HKD) and 
HKD26 million (USD3.34 million) respectively. The annual average cost per patient 
before and after RLA treatment was HKD447,300 (USD57,300) and HKD144,600 
(USD18,500) respectively. CONCLUSIONS: From the present group of patients 
assessed two years after initiation of RLA treatment, it appears that the treatment can 
potentially lead to substantial cost savings. The major cost driver appears to be hos-
pitalization due to either poor control or adverse effects of medications.
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ECONOMIC ASSESSMENT OF SECOND-LINE TREATMENT: SWITCHING 
FROM A GENERIC SSRI TO ESCITALOPRAM, AN SNRI, OR ANOTHER
GENERIC SSRI BY PATIENTS WITH MAJOR DEPRESSIVE DISORDER
(MDD)
Marynchenko M1, Yu AP2, Lauzon V1, Ramakrishnan K2, Wu EQ2, Ben-Hamadi R2, 
Erder MH3, Bose A3
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OBJECTIVES: First-line treatment of MDD patients with a generic SSRI is often 
encouraged by managed care organizations. However, some patients may require 
second line therapy. This study evaluates the economic consequences associated with 
three options of second-line treatment: escitalopram, an SNRI (venlafaxine or dulox-
etine), or a generic SSRI. METHODS: Adult MDD patients treated with a generic 
SSRI were identiﬁ ed in the Ingenix Impact database (2003–2007) and included if they 
switched to escitalopram, an SNRI, or another generic SSRI. Urgent care utilization
during the 3-month follow-up was compared across these three study cohorts. Costs 
incurred during three months pre- vs. post-switching date were compared descriptively 
and using regression analyses adjusting for patient demographics, comorbidities, prior
resource use and length of therapy. RESULTS: The study identiﬁ ed 7,774 switchers 
to escitalopram, 10,505 to SNRIs, and 6,723 to a generic SSRI. Compared to escitalo-
pram switchers, patients who switched to an SNRI or a generic SSRI had an increased
adjusted risk of mental health-related urgent care utilization (OR  1.30 and 1.17 
respectively, both P  0.05). Patients who switched to escitalopram had a $402 reduc-
tion in medical costs (P  0.001) during the 3-month follow-up period compared to
